TY - JOUR
T1 - Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer
T2 - results of a Japan Clinical Oncology Group Study (JCOG9401)
AU - Shien, Tadahiko
AU - Iwata, Hiroji
AU - Aogi, Kenjiro
AU - Fukutomi, Takashi
AU - Inoue, Kenichi
AU - Kinoshita, Takayuki
AU - Takahashi, Masato
AU - Matsui, Akira
AU - Shibata, Taro
AU - Fukuda, Haruhiko
N1 - Funding Information:
We thank Ms. Kyoko Minamoto and Kazumi Kubota for data management, Dr. Naoki Ishizuka and Mr. Junki Mizusawa for statistical analyses, and Dr. Kenichi Nakamura for the preparation of the manuscript. This study was supported by a National Cancer Center Research and Development Fund (23-A-16 and 23-A-17) and Grants-in-Aid for Cancer Research (5S-1, 8S-1, 11S-1, 11S-4, 14S-1, 14S-4, 17S-1, 17S-5, 20S-1 and 20S-6) from the Ministry of Health, Labour and Welfare, Japan.
Publisher Copyright:
© 2013, Japan Society of Clinical Oncology.
PY - 2014/12/10
Y1 - 2014/12/10
N2 - Background: Cancer subtype has recently become an increasingly important consideration when deciding the treatment strategy for breast cancer. For the estrogen receptor positive (ER+) subtype, the efficacy of adjuvant endocrine therapy is definitive, but that of adjuvant chemotherapy is controversial.Results: One hundred twenty-nine patients were recruited (TAM 64, ACT 65) between October 1994 and July 1999. The hazard ratios for OS and relapse-free survival (RFS) were 0.58 (95 % CI 0.24–1.39; log-rank p = 0.22) and 0.45 (95 %CI 0.24–0.86; log-rank p = 0.013), respectively, in favor of ACT. The 5-year OS and RFS were 76.9 % (ER+ 87.1 %, ER− 53.3 %) and 54.9 % (ER+ 59.3 %, ER− 42.9 %) for TAM and 85.0 % (ER+ 90.0 %, ER− 77.1 %) and 76.7 % (ER+ 76.9 %, ER− 76.0 %) for ACT. A higher proportion of the patients receiving ACT than those receiving TAM experienced grade 3 decreased white blood cell count and grade 2–3 nausea.Conclusion: The efficacy of adding AC to TAM was not high for ER+, node-positive PMBC. However, adjuvant ACT therapy was considered to be effective for ER−, node-positive PMBC.Methods: In order to evaluate the effect of adding doxorubicin (A) and cyclophosphamide (C) to tamoxifen (TAM) (ACT) on the overall survival (OS) of node-positive postmenopausal breast cancer (PMBC) patients, we conducted a randomized trial. Eligibility criteria included pathologically node-positive (n = 1–9) PMBC, stage I–IIIA disease. Patients were randomized to receive either TAM (20 mg daily) for 2 years or A (40 mg/m2) and C (500 mg/m2) plus TAM (ACT) as adjuvant therapy following surgery.
AB - Background: Cancer subtype has recently become an increasingly important consideration when deciding the treatment strategy for breast cancer. For the estrogen receptor positive (ER+) subtype, the efficacy of adjuvant endocrine therapy is definitive, but that of adjuvant chemotherapy is controversial.Results: One hundred twenty-nine patients were recruited (TAM 64, ACT 65) between October 1994 and July 1999. The hazard ratios for OS and relapse-free survival (RFS) were 0.58 (95 % CI 0.24–1.39; log-rank p = 0.22) and 0.45 (95 %CI 0.24–0.86; log-rank p = 0.013), respectively, in favor of ACT. The 5-year OS and RFS were 76.9 % (ER+ 87.1 %, ER− 53.3 %) and 54.9 % (ER+ 59.3 %, ER− 42.9 %) for TAM and 85.0 % (ER+ 90.0 %, ER− 77.1 %) and 76.7 % (ER+ 76.9 %, ER− 76.0 %) for ACT. A higher proportion of the patients receiving ACT than those receiving TAM experienced grade 3 decreased white blood cell count and grade 2–3 nausea.Conclusion: The efficacy of adding AC to TAM was not high for ER+, node-positive PMBC. However, adjuvant ACT therapy was considered to be effective for ER−, node-positive PMBC.Methods: In order to evaluate the effect of adding doxorubicin (A) and cyclophosphamide (C) to tamoxifen (TAM) (ACT) on the overall survival (OS) of node-positive postmenopausal breast cancer (PMBC) patients, we conducted a randomized trial. Eligibility criteria included pathologically node-positive (n = 1–9) PMBC, stage I–IIIA disease. Patients were randomized to receive either TAM (20 mg daily) for 2 years or A (40 mg/m2) and C (500 mg/m2) plus TAM (ACT) as adjuvant therapy following surgery.
KW - Adjuvant treatment
KW - Breast cancer
KW - Node-positive
KW - Postmenopausal women
UR - http://www.scopus.com/inward/record.url?scp=84907598387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907598387&partnerID=8YFLogxK
U2 - 10.1007/s10147-013-0657-z
DO - 10.1007/s10147-013-0657-z
M3 - Article
C2 - 24395447
AN - SCOPUS:84907598387
SN - 1341-9625
VL - 19
SP - 982
EP - 988
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 6
ER -
